The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Wen-Chien HuangVijesh Kumar YadavWei-Hong ChengChun-Hua WangMing-Shou HsiehTing-Yi HuangShiou-Fu Lin Chi-Tai YehKuang-Tai Kuo

Published in: Cancers (2021)

Our results suggested that MEK/ERK/miR-21 signaling is critical in Osimertinib resistance and CAF transformation of NSCLC cells, and MEK inhibitor Trametinib significantly suppressed Osimertinib-resistant NSCLC tumor growth by abolishing both processes.

Keyphrases

small cell lung cancer
pi k akt
cell proliferation
cell cycle arrest
advanced non small cell lung cancer
signaling pathway
epidermal growth factor receptor
induced apoptosis
long non coding rna
brain metastases
long noncoding rna
tyrosine kinase
single cell
cell therapy
cell death
wild type